In this role, he led the integration of Forest Laboratories following its acquisition by Actavis. He also co-leads the pre-integration planning team for the acquisition of Allergan. Prior to joining Actavis, Mr. Kelly was Senior Vice President, Chief Communications Officer, Public Affairs and Investor Relations at Forest Laboratories. In that role, he led Forest’s corporate communications and investor relations programs, including internal and external communications, media relations, corporate branding, product communications, and public affairs. While at Forest, Mr. Kelly led the integration of Aptalis Pharma following its acquisition in January 2014. Prior to Forest, Mr. Kelly served as Vice President, Investor Relations at Bausch + Lomb. Mr. Kelly was Senior Vice President, Investor Relations at Merck & Co., Inc. following the combination with Schering-Plough where he led the Global Communications and Investor Relations team. He previously worked for Novartis as Executive Director, Investor Relations, after spending 14 years at Pharmacia, including ten years in pharmaceutical sales and sales management and four years in investor relations. Mr. Kelly holds a Bachelor of Science in Pharmacy from Purdue University, where he graduated Cum Laude.